Authors : Jai Prakash Singh; Vinayak Gaur; Preeti Dubey

Volume/Issue : Volume 10 - 2025, Issue 4 - April

Google Scholar : https://tinyurl.com/ycybc5fh

Scribd : https://tinyurl.com/bdhy7u76

DOI : https://doi.org/10.38124/ijisrt/25apr1322

Google Scholar

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Note : Google Scholar may take 15 to 20 days to display the article.

Abstract : Recent advances in biomedical technology have catalyzed a transformation in pharmacological science, marking a paradigm shift from generalized, symptom-driven treatment to personalized, predictive, and precision-based therapeutics. This review explores how innovations across genomics, artificial intelligence, dose modeling, RNA-based drugs, and smart delivery systems are redefining the design, delivery, and regulation of modern therapies. We critically examine developments in pharmacogenomics, biomarker-guided therapy, dose optimization, and AI-enabled drug discovery, alongside breakthroughs in gene editing tools like CRISPR, RNA therapeutics, and digital twin simulations. Additionally, we explore the convergence of multi-omics data, predictive toxicology, and smart nanocarriers that allow for spatiotemporally controlled drug release. These innovations are enabling treatment strategies that are not only more precise but also adaptable to the unique physiological landscape of each patient. However, the promise of these innovations is tempered by challenges involving clinical integration, regulatory adaptation, and healthcare equity. The review concludes with reflections on the ethical and societal responsibilities associated with programmable pharmacology and offers insights into the future landscape of globally accessible, responsibly governed therapeutic technologies.

References :

1. Relling MV, Evans WE. Pharmacogenomics in the clinic. Nature. 2015;526(7573):343–50. doi:10.1038/nature15817
2. Paul SM, et al. How to improve R&D productivity: the pharmaceutical industry's grand challenge. Nat Rev Drug Discov. 2010;9(3):203–14.
3. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients. JAMA. 1998;279(15):1200–5.
4. DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: New estimates of R&D costs. J Health Econ. 2016;47:20–33.
5. Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747–52.
6. Johnson JA. Pharmacogenetics: potential for individualized drug therapy through genetics. Trends Genet. 2003;19(11):660–6.
7. Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med. 2015;372(9):793–5.
8. Crews KR, Gaedigk A, Dunnenberger HM, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2D6 and CYP2C19 genotypes and dosing of SSRIs. Clin Pharmacol Ther. 2021;110(6):1274–82.
9. Dienstmann R, Rodon J, Barretina J, Tabernero J. Genomic medicine frontier in human solid tumors: prospects and challenges. J Clin Oncol. 2013;31(15):1874–84.
10. Singh AB. Improved antidepressant outcomes with pharmacogenomics. Mol Psychiatry. 2022;27(1):3–6.
11. Vamathevan J, Clark D, Czodrowski P, et al. Applications of machine learning in drug discovery and development. Nat Rev Drug Discov. 2019;18(6):463–77.
12. Jamei M, Dickinson GL, Rostami-Hodjegan A. A framework for assessing inter-individual variability in pharmacokinetics using virtual populations. CPT Pharmacometrics Syst Pharmacol. 2015;4(2):72–81.
13. Zhou Y, Wang F, Tang J, Nussinov R, Cheng F. Artificial intelligence in COVID-19 drug repurposing. Trends Pharmacol Sci. 2020;41(12):1009–23.
14. Hood L, Friend SH. Predictive, personalized, preventive, participatory (P4) cancer medicine. Nat Rev Clin Oncol. 2011;8(3):184–7.
15. Ginsburg GS, Phillips KA. Precision medicine: from science to value. Health Aff (Millwood). 2018;37(5):694–701.
16. Holmes MV, Ala-Korpela M, Smith GD. Precision medicine in the era of big data. Nat Rev Drug Discov. 2017;16(6):377–89.
17. Bramer WM, Rethlefsen ML, Kleijnen J, Franco OH. Optimal database combinations for literature searches in systematic reviews: a prospective exploratory study. Syst Rev. 2017;6(1):245.
18. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097.
19. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71.
20. Thomas J, Harden A. Methods for the thematic synthesis of qualitative research in systematic reviews. BMC Med Res Methodol. 2008;8:45.
21. Relling MV, Klein TE. CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clin Pharmacol Ther. 2011;89(3):464–7.
22. Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 2013;138(1):103–41.
23. Mega JL, Simon T, Collet JP, et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel. JAMA. 2010;304(16):1821–30.
24. Caudle KE, Dunnenberger HM, Freimuth RR, et al. Standardizing terms for clinical pharmacogenetics: consensus terms from the CPIC. Genet Med. 2017;19(2):215–23.
25. Dienstmann R, Rodon J, Tabernero J. Molecular profiling for precision cancer therapies. Clin Cancer Res. 2015;21(6):1219–25.
26. Winner JG, Allen JD, Altar CA, Spahic-Mihajlovic A. Psychiatric pharmacogenomics: how close are we? Pharmacogenomics J. 2013;13(5):395–403.
27. Amstutz U, Henricks LM, Offer SM, et al. Clinical pharmacogenetics implementation of thiopurine methyltransferase and NUDT15 testing in patients receiving thiopurines. Clin Pharmacol Ther. 2018;103(4):642–9.
28. Hicks JK, Dunnenberger HM, Gumpper KF, et al. Integrating pharmacogenomics into electronic health records with clinical decision support. Am J Health Syst Pharm. 2016;73(23):1967–76.
29. Punt CJ, Koopman M, Vermeulen L. From tumour heterogeneity to advances in precision treatment of colorectal cancer. Nat Rev Clin Oncol. 2017;14(4):235–46.
30. Pao W, Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol. 2011;12(2):175–80.
31. Garrison LP Jr, Neumann PJ, Erickson P, Marshall D, Mullins CD. Using real-world data for coverage and payment decisions: the ISPOR real-world data task force report. Value Health. 2007;10(5):326–35.
32. McDermott DF, Atkins MB. PD-1 as a potential target in cancer therapy. Cancer Med. 2013;2(5):662–73.
33. Altar CA, Carhart JM, Allen JD, Hall-Flavin DK, Dechairo BM, Winner JG. Clinical validity of combinatorial pharmacogenomics for guiding antidepressant treatment. Psychiatr Genet. 2015;25(6):306–17.
34. Maisel A, Mueller C, Adams K Jr, et al. State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail. 2008;10(9):824–39.
35. Simon R. Critical review of biomarker-based clinical trial design and analysis. J Clin Oncol. 2010;28(20):2787–94.
36. Rowland M, Tozer TN. Clinical Pharmacokinetics and Pharmacodynamics: Concepts and Applications. 5th ed. Lippincott Williams & Wilkins; 2021.
37. Zhao P, Zhang L, Grillo JA, et al. Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review. Clin Pharmacol Ther. 2011;89(2):259–67.
38. Abduljalil K, Jamei M, Rostami-Hodjegan A. Virtual clinical trials in pediatrics: applications, gaps, and challenges. Clin Pharmacol Ther. 2014;96(3):265–77.
39. Jones HM, Chen Y, Gibson C, et al. Physiologically based pharmacokinetic modeling in drug discovery and development: a pharmaceutical industry perspective. Clin Pharmacol Ther. 2015;97(3):247–62.
40. Gabrielsson J, Weiner D. Pharmacokinetic and Pharmacodynamic Data Analysis: Concepts and Applications. 5th ed. CRC Press; 2016.
41. Derendorf H, Meibohm B. Modeling of pharmacokinetic/pharmacodynamic relationships: concepts and perspectives. Pharm Res. 1999;16(2):176–85.
42. Mould DR, Upton RN. Basic concepts in population modeling, simulation, and model-based drug development. CPT Pharmacometrics Syst Pharmacol. 2012;1(9):e6.
43. Roberts JA, Abdul-Aziz MH, Lipman J, Mouton JW, Vinks AA, Felton TW. Individualised antibiotic dosing for critically ill patients: challenges and potential solutions. Lancet Infect Dis. 2014;14(6):498–509.
44. Schuck E. Machine learning in pharmacodynamics: enabling adaptive dose-response modeling. J Clin Pharmacol. 2022;62(1):8–17.
45. Roden DM, Wilke RA, Kroemer HK, Stein CM. Pharmacogenomics: the genetics of variable drug responses. Circulation. 2011;123(15):1661–70.
46. Johnson JA, Cavallari LH. Warfarin pharmacogenetics. Trends Cardiovasc Med. 2015;25(1):33–41.
47. Yang JJ, Landier W, Yang W, et al. Inherited NUDT15 variants and thiopurine-related hematotoxicity in children with acute lymphoblastic leukemia. JAMA. 2015;313(10):937–46.
48. Caudle KE, Dunnenberger HM, Freimuth RR, et al. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2D6 and codeine therapy. Clin Pharmacol Ther. 2014;95(4):376–82.
49. Petrovski S, Goldstein DB. Unequal representation of genetic variation across ancestry groups creates healthcare inequality in the application of precision medicine. Genome Biol. 2016;17(1):157.
50. Wright A, Sittig DF, Ash JS, Sharma S, Pang JE, Middleton B. Clinical decision support capabilities of commercially available clinical information systems. J Am Med Inform Assoc. 2009;16(5):637–44.
51. Evans WE, Relling MV. Moving towards individualized medicine with pharmacogenomics. Nature. 2004;429(6990):464–8.
52. Hershfield MS, Callaghan JT, Tassaneeyakul W, et al. Clinical pharmacogenetics implementation consortium guidelines for HLA-B*58:01 genotype and allopurinol dosing. Clin Pharmacol Ther. 2013;93(2):153–8.
53. Hoffman JM, Haidar CE, Wilkinson MR, et al. PG4KDS: A model for the clinical implementation of preemptive pharmacogenetics. Am J Med Genet C Semin Med Genet. 2014;166C(1):45–55.
54. Bell GC, Crews KR, Wilkinson MR, et al. Development and use of active clinical decision support for preemptive pharmacogenomics. J Am Med Inform Assoc. 2014;21(e1):e93–e99.
55. Mandel JC, Kreda DA, Mandl KD, Kohane IS, Ramoni RB. SMART on FHIR: a standards-based, interoperable apps platform for electronic health records. J Am Med Inform Assoc. 2016;23(5):899–908.
56. Luzum JA, Pakyz RE, Elsey AR, Haidar CE, Peterson JF, Whirl-Carrillo M, et al. The pharmacogenomics education gap: challenges for practicing clinicians. Am J Med Genet C Semin Med Genet. 2014;166C(1):52–7.
57. Popejoy AB, Fullerton SM. Genomics is failing on diversity. Nature. 2016;538(7624):161–4.
58. Tutton R, Prainsack B. Enterprising or altruistic selves? Making up research subjects in genetics research. Sociol Health Illn. 2011;33(7):1081–95.
59. Viceconti M, Hunter P, Hose R. Big data, big knowledge: big data for personalized healthcare. IEEE J Biomed Health Inform. 2015;19(4):1209–15.
60. Bank PCD, Caudle KE, Swen JJ, Gammal RS, Whirl-Carrillo M, Klein TE, et al. Comparison of the guidelines of the Clinical Pharmacogenetics Implementation Consortium and the Dutch Pharmacogenetics Working Group. Clin Pharmacol Ther. 2018;103(4):599–618.
61. Samwald M, Hanbury A, Adlassnig KP, et al. Pharmacogenomic knowledge representation, reasoning and genome-based clinical decision support based on OWL 2 DL ontologies. BMC Med Inform Decis Mak. 2015;15:12.
62. Marjanovic S, Harshfield A, Carpenter A, et al. Realising the promise of stratified medicine. RAND Health Q. 2017;6(3):1.
63. Stanek EJ, Sanders CL, Taber KA, et al. Adoption of pharmacogenomic testing by US physicians: results of a nationwide survey. Clin Pharmacol Ther. 2012;91(3):450–8.
64. Roosan D, Samore MH, Min J, et al. Exploring barriers to pharmacogenomic testing in clinical practice. J Am Pharm Assoc. 2019;59(5):697–703.
65. Lu CY, Loomer S, Ceccarelli R, et al. Clinical implementation of pharmacogenetic decision support for thiopurines: challenges and lessons learned. Genet Med. 2014;16(8):613–20.
66. Vassy JL, Christensen KD, Schonman EF, et al. The impact of preemptive pharmacogenomic testing on medication prescribing: a randomized clinical trial. JAMA Intern Med. 2017;177(7):1063–70.
67. Ramos EM, Din-Lovinescu C, Bookman EB, et al. Pharmacogenomics research and implementation in diverse populations—points to consider. Pharmacogenomics J. 2014;14(4):357–62.
68. Popejoy AB, Fullerton SM. Genomics is failing on diversity. Nature. 2016;538(7624):161–4.
69. Blagec K, Romagnoli KM, Boyce RD, et al. Shared decision-making in pharmacogenomics: insights from the U-PGx implementation program. Genet Med. 2021;23(6):1138–45.
70. Vamathevan J, Clark D, Czodrowski P, et al. Applications of machine learning in drug discovery and development. Nat Rev Drug Discov. 2019;18(6):463–77.
71. Waring MJ, Arrowsmith J, Leach AR, et al. An analysis of the attrition of drug candidates from four major pharmaceutical companies. Nat Rev Drug Discov. 2015;14(7):475–86.
72. Mayr A, Klambauer G, Unterthiner T, et al. DeepTox: toxicity prediction using deep learning. Front Environ Sci. 2016;3:80.
73. Xiong G, Wu Z, Yi J, Fu L, Yang Z, Hsieh C, et al. ADMETlab 2.0: an integrated online platform for accurate and comprehensive predictions of ADMET properties. Nucleic Acids Res. 2021;49(W1):W5–14.
74. Zhang W, Chen Y, Liu F, et al. Predicting potential drug–drug interactions by integrating chemical, biological, phenotypic and network data. BMC Bioinformatics. 2017;18(1):18.
75. Holzinger A, Biemann C, Pattichis CS, Kell DB. What do we need to build explainable AI systems for the medical domain? Rev Artif Intell. 2017;26(2):237–49.
76. Pushpakom S, Iorio F, Eyers PA, et al. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov. 2019;18(1):41–58.
77. Richardson P, Griffin I, Tucker C, et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet. 2020;395(10223):e30–e31.
78. Zitnik M, Agrawal M, Leskovec J. Modeling polypharmacy side effects with graph convolutional networks. Bioinformatics. 2018;34(13):i457–i466.
79. Subramanian A, Narayan R, Corsello SM, et al. A next-generation connectivity map: L1000 platform and the first 1,000,000 profiles. Cell. 2017;171(6):1437–1452.e17.
80. Lee J, Yoon W, Kim S, et al. BioBERT: a pre-trained biomedical language representation model for biomedical text mining. Bioinformatics. 2020;36(4):1234–40.
81. Wallach I, Dzamba M, Heifets A. AtomNet: a deep convolutional neural network for bioactivity prediction in structure-based drug discovery. arXiv. 2015;1503.
82. Stebbing J, Phelan A, Griffin I, et al. COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis. 2020;20(4):400–2.
83. Bruynseels K, Santoni de Sio F, van den Hoven J. Digital twins in health care: ethical implications of an emerging engineering paradigm. Front Genet. 2018;9:31.
84. Björnsson B, Borrebaeck C, Elander N, Gasslander T, Gawel DR, Gustafsson M, et al. Digital twins to personalize medicine. Genome Med. 2020;12(1):4.
85. Viceconti M, Hunter P, Hose R. Big data, big knowledge: big data for personalized healthcare. IEEE J Biomed Health Inform. 2015;19(4):1209–15.
86. Corral-Acero J, Margara F, Marciniak M, et al. The ‘digital twin’ to enable the vision of precision cardiology. Eur Heart J. 2020;41(48):4556–64.
87. Horgan D, Hackett J, Westphalen CB, et al. Digital twins and the future of precision medicine. Biomed Hub. 2021;6(3):85–96.
88. European Medicines Agency (EMA). EMA Regulatory Science to 2025: Advancing human and veterinary medicines regulation to respond to patients’ needs. EMA; 2020.
89. Hasin Y, Seldin M, Lusis A. Multi-omics approaches to disease. Genome Biol. 2017;18(1):83.
90. Wang B, Mezlini AM, Demir F, et al. Similarity network fusion for aggregating data types on a genomic scale. Nat Methods. 2014;11(3):333–7.
91. Krug K, Mertins P, Zhang B, et al. A curated resource for phosphosite-specific signature analysis. Mol Cell Proteomics. 2019;18(3):576–93.
92. Rhoades SD, Weljie AM, Barnett DA. NMR-based metabolomics in the clinical laboratory: current status and potential applications. Analyst. 2017;142(1):33–44.
93. Zhou Y, Zhou B, Pache L, et al. Metascape provides a biologist-oriented resource for the analysis of systems-level datasets. Nat Commun. 2019;10(1):1523.
94. Dai D, Luo X, Xiong H, et al. Multi-omics data integration in cancer: recent advances and future perspectives. Biol Proced Online. 2020;22(1):10.
95. Ma X, Liu Y, Liu Y, et al. Omics-based personalized medicine: the future is now. Brief Bioinform. 2021;22(1):bbaa120.
96. Hartung T. Revolution in toxicology: from in vivo to in vitro to in silico. ALTEX. 2009;26(2):77–83.
97. Thomas RS, Philbert MA, Auerbach SS, et al. Incorporating new technologies into toxicity testing and risk assessment: moving from 21st century vision to a data-driven framework. Toxicol Sci. 2013;136(1):4–18.
98. Zhang Q, Yin L, Lu H, et al. Graph-based modeling and prediction of drug-induced liver injury. Bioinformatics. 2021;37(3):351–9.
99. Mayr A, Klambauer G, Unterthiner T, Hochreiter S. DeepTox: toxicity prediction using deep learning. Front Environ Sci. 2016;3:80.
100. Greene N, Judson PN, Langowski JJ, Marchant CA. Knowledge-based expert systems for toxicity and metabolism prediction: DEREK, StAR and METEOR. SAR QSAR Environ Res. 1999;10(2–3):299–314.
101. OECD. Guidance Document on the Validation of (Quantitative) Structure–Activity Relationship [(Q)SAR] Models. OECD Series on Testing and Assessment. Paris: OECD Publishing; 2007.
102. Goh GB, Hodas NO, Vishnu A. Deep learning for computational chemistry. J Comput Chem. 2017;38(16):1291–302.
103. Knott GJ, Doudna JA. CRISPR-Cas guides the future of genetic engineering. Science. 2018;361(6405):866–9.
104. Frangoul H, Altshuler D, Cappellini MD, et al. CRISPR-Cas9 gene editing for sickle cell disease and β-thalassemia. N Engl J Med. 2021;384(3):252–60.
105. Anzalone AV, Randolph PB, Davis JR, et al. Search-and-replace genome editing without double-strand breaks or donor DNA. Nature. 2019;576(7785):149–57.
106. Hua Y, Sahashi K, Rigo F, et al. Peripheral SMN restoration improves disease symptoms in SMA mice. J Clin Invest. 2011;121(8):3029–41.
107. Adams D, Gonzalez-Duarte A, O'Riordan WD, et al. Patisiran, an RNAi therapeutic for hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):11–21.
108. Kulkarni JA, Witzigmann D, Thomson SB, et al. The current landscape of nucleic acid therapeutics. Nat Nanotechnol. 2021;16(6):630–43.
109. WHO Expert Advisory Committee on Developing Global Standards for Governance and Oversight of Human Genome Editing. WHO Report 2021.
110. Mitragotri S, Burke PA, Langer R. Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies. Nat Rev Drug Discov. 2014;13(9):655–72.
111. Peer D, Karp JM, Hong S, et al. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007;2(12):751–60.
112. Torchilin VP. Multifunctional nanocarriers. Adv Drug Deliv Rev. 2006;58(14):1532–55.
113. Farokhzad OC, Langer R. Impact of nanotechnology on drug delivery. ACS Nano. 2009;3(1):16–20.
114. Saraiva C, Praça C, Ferreira R, et al. Nanoparticle-mediated brain drug delivery: overcoming blood–brain barrier to treat neurodegenerative diseases. J Control Release. 2016;235:34–47.
115. Lee H, Song C, Hong YS, et al. Wearable/disposable sweat-based glucose monitoring device with multistage transdermal drug delivery module. Sci Adv. 2017;3(3):e1601314.
116. U.S. Food and Drug Administration (FDA). Drug-Device Combination Products. Guidance for Industry. 2020.
117. Kitano H. Systems biology: a brief overview. Science. 2002;295(5560):1662–4.
118. Barabási AL, Gulbahce N, Loscalzo J. Network medicine: a network-based approach to human disease. Nat Rev Genet. 2011;12(1):56–68.
119. Ahlqvist E, Storm P, Käräjämäki A, et al. Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis. Lancet Diabetes Endocrinol. 2018;6(5):361–9.
120. Berger SI, Iyengar R. Network analyses in systems pharmacology. Bioinformatics. 2009;25(19):2466–72.
121. Mittelstadt BD, Floridi L. The ethics of big data: current and foreseeable issues in biomedical contexts. Sci Eng Ethics. 2016;22(2):303–41.
122. Coravos A, Goldsack JC, Karlin DR, et al. Digital medicine: a primer on measurement. Digit Biomark. 2019;3(2):31–71.
123. EMA. Reflection paper on the use of real-world data in regulatory decision-making. EMA; 2021.
124. Popejoy AB, Fullerton SM. Genomics is failing on diversity. Nature. 2016;538(7624):161–4.
125. WHO. Global governance of genome editing: WHO’s Advisory Committee 2021 Final Report. Geneva: World Health Organization; 2021.